Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Geroscience Approach to Post-acute COVID-19 Syndrome with Diet/Exercise plus Rapamycin or Metformin
2023-504641-32-00Phase 2Withdrawn
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in post-COVID syndrome and Fragility comparing Diet and exercise plus metformin with Diet and exercise plus sirolimus (2 arms). Primary endpoints: Short Physical Performance Battery, Frailty reversibility and 1 more. Planned start Jul 2023; status: withdrawn.
02
Drugs
metforminsirolimus
03
Conditions
post-COVID syndromeFragility
Beyond the preview
Go deeper on 2023-504641-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504641-32-00.